A detailed history of Bank Of America Corp transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Bank Of America Corp holds 547,818 shares of RARE stock, worth $27.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
547,818
Previous 430,536 27.24%
Holding current value
$27.7 Million
Previous $20.1 Million 12.01%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$37.42 - $51.61 $4.39 Million - $6.05 Million
117,282 Added 27.24%
547,818 $22.5 Million
Q1 2024

May 15, 2024

BUY
$43.02 - $53.69 $3.75 Million - $4.68 Million
87,124 Added 25.37%
430,536 $20.1 Million
Q4 2023

Feb 14, 2024

SELL
$31.73 - $49.19 $490,355 - $760,182
-15,454 Reduced 4.31%
343,412 $16.4 Million
Q2 2023

Aug 14, 2023

SELL
$37.35 - $52.15 $4.19 Million - $5.85 Million
-112,084 Reduced 23.8%
358,866 $16.6 Million
Q1 2023

May 12, 2023

BUY
$36.99 - $48.71 $2.91 Million - $3.83 Million
78,556 Added 20.02%
470,950 $18.9 Million
Q4 2022

Feb 10, 2023

BUY
$33.72 - $46.33 $849,676 - $1.17 Million
25,198 Added 6.86%
392,394 $18.2 Million
Q3 2022

Nov 14, 2022

SELL
$39.96 - $66.14 $1.86 Million - $3.08 Million
-46,535 Reduced 11.25%
367,196 $15.2 Million
Q2 2022

Aug 12, 2022

BUY
$45.8 - $85.4 $3.58 Million - $6.68 Million
78,248 Added 23.32%
413,731 $24.7 Million
Q1 2022

May 16, 2022

BUY
$62.2 - $84.4 $5.52 Million - $7.49 Million
88,687 Added 35.94%
335,483 $24.4 Million
Q4 2021

Feb 08, 2022

SELL
$73.71 - $87.86 $1.33 Million - $1.59 Million
-18,077 Reduced 6.82%
246,796 $20.8 Million
Q3 2021

Nov 15, 2021

BUY
$77.92 - $102.4 $2.21 Million - $2.9 Million
28,365 Added 11.99%
264,873 $23.9 Million
Q2 2021

Sep 13, 2021

BUY
$92.19 - $115.71 $21.8 Million - $27.4 Million
236,508 New
236,508 $22.6 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $3.54B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.